Who are ZSP1273's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Sofosbuvir and Daklatasuvir.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/zsp1273.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

ZSP1273 — Competitive Intelligence Brief

ZSP1273 (ZSP1273) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: RNA-dependent RNA polymerase inhibitor. Area: Infectious Diseases.

phase 3 RNA-dependent RNA polymerase inhibitor Influenza virus RNA-dependent RNA polymerase Infectious Diseases Small molecule Live · refreshed every 30 min

Target snapshot

ZSP1273 (ZSP1273) — Guangdong Raynovent Biotech Co., Ltd. ZSP1273 is an influenza virus RNA-dependent RNA polymerase inhibitor that blocks viral replication.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
ZSP1273 TARGET	ZSP1273	Guangdong Raynovent Biotech Co., Ltd	phase 3	RNA-dependent RNA polymerase inhibitor	Influenza virus RNA-dependent RNA polymerase
Sofosbuvir and Daklatasuvir	Sofosbuvir and Daklatasuvir	Sherief Abd-Elsalam	phase 3	NS5B RNA-dependent RNA polymerase inhibitor and NS5A inhibitor	HCV NS5B RNA-dependent RNA polymerase and HCV NS5A protein

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (RNA-dependent RNA polymerase inhibitor class)

Guangdong Raynovent Biotech Co., Ltd · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ZSP1273 — Competitive Intelligence Brief. https://druglandscape.com/ci/zsp1273. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab